Contact:Jonni Thoma
Phone:(434)982-6714
E-mail:mjh4a@virginia.edu
Health System, Human Immune Therapy Center, seeks participants with melanoma for a research study.
The purpose of this study is to find out what effects drugs CCI-779 and bevacizumab have on participants and melanoma. CCI-779 is an experimental anti-cancer agent that has not yet been approved by the Food and Drug Administration for use in melanoma or in any other cancer. Bevacizumab is an experimental anti-cancer agent that has not yet been approved by the Food and Drug Administration for use in melanoma.
If you should decide to participate in the study, you will undergo CT, MRI, and bone scans; physical examinations, biopsies, answer questions regarding your medical history, have an EKG, as well as urine and blood tests. You will undergo as many as 26 cycles of treatment (each cycle lasts 14 days; thus, up to one year of treatment). Each cycle consists of treatment on days 1, 8, and 11 of each cycle, and may include infusions, scans, physical exams, biopsies, and blood tests. Treatments take place in the UVA Health System Cancer Center. Two overnight visits in the GCRC at the UVA Health System may be required. After treatment, you may have a doctor's visit scheduled every three months for followup.
There is no compensation available for participants in this study.
Contact Information:
For more information please contact:
Mary J Thoma, mjh4a@virginia.edu
IRB-HSR #12471
Principal Investigator: Craig Slingluff, Jr., MD
|
|
Primary Investigator: Slingluff Craig, L